| __timestamp | ACADIA Pharmaceuticals Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 60602000 | 79696000 |
| Thursday, January 1, 2015 | 73869000 | 93236000 |
| Friday, January 1, 2016 | 99284000 | 150842000 |
| Sunday, January 1, 2017 | 149189000 | 150643000 |
| Monday, January 1, 2018 | 187163000 | 150252000 |
| Tuesday, January 1, 2019 | 240385000 | 140804000 |
| Wednesday, January 1, 2020 | 319130000 | 34236000 |
| Friday, January 1, 2021 | 239415000 | 35672000 |
| Saturday, January 1, 2022 | 361575000 | 66607000 |
| Sunday, January 1, 2023 | 351619000 | 76363000 |
Unleashing insights
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, ACADIA Pharmaceuticals Inc. and Halozyme Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, ACADIA Pharmaceuticals increased its R&D expenses by nearly 480%, peaking in 2022 with a 361% rise compared to 2014. In contrast, Halozyme Therapeutics saw a more modest increase of approximately 4% over the same period, with a notable dip in 2020. This divergence highlights ACADIA's aggressive pursuit of new therapies, while Halozyme appears to adopt a more conservative strategy. As the biotech landscape evolves, these spending patterns may influence each company's ability to innovate and capture market share. Understanding these trends provides valuable insights into the strategic priorities of these industry players.
Who Prioritizes Innovation? R&D Spending Compared for Zoetis Inc. and Halozyme Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs ACADIA Pharmaceuticals Inc.
Research and Development: Comparing Key Metrics for Halozyme Therapeutics, Inc. and Pharming Group N.V.
Halozyme Therapeutics, Inc. vs Xenon Pharmaceuticals Inc.: Strategic Focus on R&D Spending
R&D Spending Showdown: Halozyme Therapeutics, Inc. vs Perrigo Company plc
R&D Insights: How Halozyme Therapeutics, Inc. and ImmunityBio, Inc. Allocate Funds
R&D Insights: How Halozyme Therapeutics, Inc. and Mesoblast Limited Allocate Funds
R&D Insights: How Halozyme Therapeutics, Inc. and Dynavax Technologies Corporation Allocate Funds
Research and Development Expenses Breakdown: ACADIA Pharmaceuticals Inc. vs Geron Corporation
R&D Spending Showdown: ACADIA Pharmaceuticals Inc. vs Taro Pharmaceutical Industries Ltd.
R&D Spending Showdown: ACADIA Pharmaceuticals Inc. vs Evotec SE